Poniard Pharmaceuticals Inc
Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplat… Read more
Poniard Pharmaceuticals Inc (PARD) - Net Assets
Latest net assets as of September 2011: $3.12 Million USD
Based on the latest financial reports, Poniard Pharmaceuticals Inc (PARD) has net assets worth $3.12 Million USD as of September 2011.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.74 Million) and total liabilities ($4.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.12 Million |
| % of Total Assets | 40.29% |
| Annual Growth Rate | -5.06% |
| 5-Year Change | -81.97% |
| 10-Year Change | -79.74% |
| Growth Volatility | 295.44 |
Poniard Pharmaceuticals Inc - Net Assets Trend (1988–2010)
This chart illustrates how Poniard Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Poniard Pharmaceuticals Inc (1988–2010)
The table below shows the annual net assets of Poniard Pharmaceuticals Inc from 1988 to 2010.
| Year | Net Assets | Change |
|---|---|---|
| 2010-12-31 | $8.45 Million | -64.25% |
| 2009-12-31 | $23.64 Million | -50.38% |
| 2008-12-31 | $47.65 Million | -46.53% |
| 2007-12-31 | $89.11 Million | +90.03% |
| 2006-12-31 | $46.89 Million | +1377.81% |
| 2005-12-31 | $3.17 Million | -84.77% |
| 2004-12-31 | $20.83 Million | -29.37% |
| 2003-12-31 | $29.49 Million | +67.79% |
| 2002-12-31 | $17.58 Million | -57.87% |
| 2001-12-31 | $41.72 Million | -32.98% |
| 2000-12-31 | $62.24 Million | +249.69% |
| 1999-12-31 | $17.80 Million | -38.62% |
| 1998-12-31 | $29.00 Million | -13.17% |
| 1997-12-31 | $33.40 Million | +95.32% |
| 1996-12-31 | $17.10 Million | +14.77% |
| 1995-12-31 | $14.90 Million | -5.70% |
| 1994-12-31 | $15.80 Million | -41.04% |
| 1993-12-31 | $26.80 Million | +84.83% |
| 1992-12-31 | $14.50 Million | +61.11% |
| 1991-12-31 | $9.00 Million | -28.00% |
| 1990-12-31 | $12.50 Million | -3.10% |
| 1989-12-31 | $12.90 Million | -51.32% |
| 1988-12-31 | $26.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Poniard Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41344300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2010)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $971.00K | 11.49% |
| Other Comprehensive Income | $8.00K | 0.09% |
| Other Components | $446.42 Million | 5281.17% |
| Total Equity | $8.45 Million | 100.00% |
Poniard Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Poniard Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Circuit Research Labs Inc
PINK:CRLI
|
$0.92 |
|
Colombia Energy Resources Inc
PINK:CERX
|
$0.92 |
|
Merriman Holdings Inc
PINK:MERR
|
$0.92 |
|
Mansfelder Metals Ltd
PINK:MNSF
|
$0.92 |
|
Commerce Group Corp
PINK:CGCO
|
$0.92 |
|
C=Holdings B.V
OTCGREY:CBUIF
|
$0.92 |
|
TFN Football Network
PINK:TFBN
|
$0.92 |
|
EnerNorth Industries Inc
OTCGREY:ENYNF
|
$0.92 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Poniard Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2009 to 2010, total equity changed from 23,644,000 to 8,453,000, a change of -15,191,000 (-64.2%).
- Net loss of 30,051,000 reduced equity.
- Dividend payments of 192,000 reduced retained earnings.
- Share repurchases of 192,000 reduced equity.
- Other comprehensive income increased equity by 25,000.
- Other factors increased equity by 15,219,000.
Equity Change Factors (2009 to 2010)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.05 Million | -355.51% |
| Dividends Paid | $192.00K | -2.27% |
| Share Repurchases | $192.00K | -2.27% |
| Other Comprehensive Income | $25.00K | +0.3% |
| Other Changes | $15.22 Million | +180.04% |
| Total Change | $- | -64.25% |
Book Value vs Market Value Analysis
This analysis compares Poniard Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1988-12-31 | $2214.61 | $0.00 | x |
| 1989-12-31 | $852.50 | $0.00 | x |
| 1990-12-31 | $812.90 | $0.00 | x |
| 1991-12-31 | $573.14 | $0.00 | x |
| 1992-12-31 | $522.00 | $0.00 | x |
| 1993-12-31 | $769.05 | $0.00 | x |
| 1994-12-31 | $327.78 | $0.00 | x |
| 1995-12-31 | $272.05 | $0.00 | x |
| 1996-12-31 | $262.96 | $0.00 | x |
| 1997-12-31 | $443.65 | $0.00 | x |
| 1998-12-31 | $332.84 | $0.00 | x |
| 1999-12-31 | $203.02 | $0.00 | x |
| 2000-12-31 | $626.16 | $0.00 | x |
| 2001-12-31 | $379.12 | $0.00 | x |
| 2002-12-31 | $158.28 | $0.00 | x |
| 2003-12-31 | $254.75 | $0.00 | x |
| 2004-12-31 | $165.80 | $0.00 | x |
| 2005-12-31 | $22.62 | $0.00 | x |
| 2006-12-31 | $107.94 | $0.00 | x |
| 2007-12-31 | $115.86 | $0.00 | x |
| 2008-12-31 | $54.95 | $0.00 | x |
| 2009-12-31 | $26.81 | $0.00 | x |
| 2010-12-31 | $7.22 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Poniard Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -355.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.38x
- Recent ROE (-355.51%) is below the historical average (-108.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1988 | -52.45% | -231.67% | 0.17x | 1.32x | $-16.55 Million |
| 1989 | -106.98% | -202.94% | 0.13x | 3.94x | $-15.09 Million |
| 1990 | -142.40% | -741.67% | 0.09x | 2.06x | $-19.05 Million |
| 1991 | -130.00% | -2925.00% | 0.02x | 2.34x | $-12.60 Million |
| 1992 | -19.31% | -30.43% | 0.50x | 1.28x | $-4.25 Million |
| 1993 | -31.72% | -229.73% | 0.12x | 1.11x | $-11.18 Million |
| 1994 | -70.25% | -693.75% | 0.08x | 1.27x | $-12.68 Million |
| 1995 | -82.55% | -4100.00% | 0.02x | 1.24x | $-13.79 Million |
| 1996 | -52.63% | -187.50% | 0.23x | 1.20x | $-10.71 Million |
| 1997 | -7.78% | -25.00% | 0.29x | 1.09x | $-5.94 Million |
| 1998 | -15.17% | -48.35% | 0.28x | 1.12x | $-7.30 Million |
| 1999 | -67.42% | -2000.00% | 0.03x | 1.17x | $-13.78 Million |
| 2000 | -18.32% | -321.27% | 0.06x | 1.04x | $-17.63 Million |
| 2001 | -57.06% | -828.47% | 0.06x | 1.22x | $-27.97 Million |
| 2002 | -131.39% | -208.91% | 0.43x | 1.48x | $-24.85 Million |
| 2003 | -17.15% | -48.04% | 0.30x | 1.21x | $-8.01 Million |
| 2004 | -93.00% | -1908.47% | 0.04x | 1.32x | $-21.45 Million |
| 2005 | -661.74% | -139980.00% | 0.00x | 3.19x | $-21.31 Million |
| 2006 | -49.68% | 0.00% | 0.00x | 1.47x | $-27.98 Million |
| 2007 | -36.79% | 0.00% | 0.00x | 1.18x | $-41.69 Million |
| 2008 | -101.93% | 0.00% | 0.00x | 1.77x | $-53.33 Million |
| 2009 | -193.35% | 0.00% | 0.00x | 2.22x | $-48.08 Million |
| 2010 | -355.51% | 0.00% | 0.00x | 1.38x | $-30.90 Million |
Industry Comparison
This section compares Poniard Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Poniard Pharmaceuticals Inc (PARD) | $3.12 Million | -52.45% | 1.48x | $0.92 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |